The article evaluates the results of Riamilovir use in treatment of patients with a moderate form of the disease caused by a new strain of the SARS-CoV-2 virus. It was found that the average time required to complete resolution of symptoms during treatment with the drug was 6-7 days. The first negative result of PCR analysis for the SARS-CoV-2 virus was registered on the 10-11th day of therapy; two consecutive negative PCR results for the SARS-CoV-2 virus were registered in the majority of patients by day 14–19 of treatment in 63±4.28%. The body temperature of the majority of patients (75%) returned to normal by the 4th day of treatment. CT scan showed improvement in the lungs of patients: a repeated CT scan performed on average on day 19 from the start of therapy showed no lung damage or no progression in 10±3.0% of patients following therapy. The CT scan of the lungs performed in 1-2 months after the treatment showed that the number of patients with no lung damage increased to 27±4.44%. As a result of treatment, a decrease in the C-reactive protein index was observed in patients. The tolerability level of the drug was assessed as good: no adverse events or significant deviations in laboratory parameters were detected.

Aim. The assessment of the effectiveness, safety and tolerance of the drug Riamilovir for emergency drug prevention in the foci of a new coronavirus infection (COVID-19). Materials and methods. The trial included 113 persons aged 18 years and older who had level 1 contacts with patients with a new coronavirus infection (COVID-19), who had not previously been ill, with negative PCR results for COVID-19. Results. The high effectiveness, safety and good tolerance of the preventive use of the drug Riamilovir for the period of 20 days of taking a prophylactic dose of 1 capsule (250 mg) per day in the foci of COVID-19 has been established. Conclusion. The effectiveness and safety of the preventive use of the drug Riamilovir allow to recommend it for emergency drug prophylaxis in contact persons in the foci of a new coronavirus infection (COVID-19).

The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin® (Riamilovir) efficacy in etiotropic therapy of influenza.Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).Results. The conducted meta-analysis showed that the use of Triazavirin® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.Conclusion. Clinical studies have shown that the use of Triazavirin® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu® (Oseltamivir) group.

No abstract